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Abstract 
Background: One of the major and life-threatening side effects of Assisted 
Reproductive Technique (ART) is ovarian hyperstimulation syndrome (OHSS). The 
available data however, have been showed that both Cabergoline (anti VEGF) and 
coasting reduce the severity of OHSS.  
Objective: We aimed to compare coasting and Cabergoline administration in 
prevention of severe OHSS.  
Materials and Methods: A total of 60 IVF/ICSI cycles were selected. Patients at risk 
of developing OHSS were divided into two groups as patient's convenience. For 30 
patients in coasting group, exogenous gonadotropins were withheld to allow E2 to 
decrease while GnRH-a was maintained. Then 10,000 unit hCG was administrated and 
oocyte retrieval was performed 36 hours later. In Cabergoline group, 30 patients were 
administered with 0.5mg Cabergoline tablet on day of hCG injection, continued for 8 
days. 
Results: The mean number of retrieved, good quality, mature oocytes and the mean 
number of embryos were significantly different in two groups (p<0.05). The clinical 
pregnancy rate was 13.3% in coasting and 26.7% in Cabergoline group that was not 
significantly different (p>0.05). The incidence of severe OHSS was similar in two 
groups.  
Conclusion: The Cabergoline was as effective as coasting in the prevention of early 
severe OHSS in high risk patients, but yielded more retrieved oocytes. 
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Introduction 
 
     The most serious and potentially life 
threatening iatrogenic complication of controlled 
ovarian hyperstimulation (COH) is a severe form 
of ovarian hyperstimulation syndrome (OHSS) (1, 
2).  It complicates less than 0.5-2% of In Vitro 
Fertilization (IVF) cycles (3) which cause 
mortality in 1/45000 – 1/50000 per infertile 
women receiving gonadotrophins (4). OHSS has 
been treated empirically over the years, because it 
is pathophysiology remained unknown.  
     The risk of OHSS increases with high serum  E2 
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levels and a large number of ovarian follicles, 
because the granulosa cells might secret not only 
sex steroids but also the vasoactive substances 
responsible for OHSS (1). Complications rarely 
manifest before the administration of human 
chorionic gonadotropin (hCG) to induce the final 
oocyte maturation .Vascular endothelial growth 
factor (VEGF) is the most important mediator of 
hCG dependent ovarian angiogenesis. VEGF not 
only stimulates new blood vessel development in 
ovary, but also induces vascular hyper 
permeability by interacting with VEGF receptor 2 
(5, 6).  Once the syndrome occurs, little can be 
done to change the course of events, only 
supportive measures can be performed, however 
the definite and useful method in this stage is cycle 
cancelling or preventing of hCG administration. 
Many methods have been tried to prevent the 
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syndrome. The appropriate stimulation protocol 
and gonadotropin needs to be selected (7). 
Unilateral ovarian follicular aspiration prior to the 
administration of hCG was successful in some 
investigations (8). In our previous study, aspiration 
of half of follicles before hCG administration 
reduced the risk of severe OHSS (9). 
Cryopreservation of all embryos has no effect on 
the syndrome occurring in the days immediately 
following oocyte retrieval, but eliminates the risk 
of early pregnancy OHSS. It takes a good success 
rate at subsequent frozen – thawed transfers (10). 
Another method for preventing OHSS is coasting 
approach. Withholding gonadotropin adminis-
tration has been employed in ovulation induction 
cycles to prevent excessive response (11-13). This 
was used in gonadotropin-releasing hormone 
analogue-treated patients (14). Recently a 
dopamine agonist, Cabergoline has been used 
successfully for prevention of severe OHSS (15).   
     The purpose of this prospective study was two 
folds: 1) to assess the effect of Cabergoline on 
cycle outcome and preventing severe OHSS and 2) 
to compare it with popular coasting method. To 
our knowledge, this is the first study which 
compares coasting with a pathophysiological 
approach. 
 
Materials and methods 
 
Patients 
     The study was approved by ethical committee 
of Research and Clinical Center for Infertility, 
Yazd University of Medical Sciences and it is was 
supported by a grant from the Research Deputy of 
Yazd University of Medical Sciences. The written 
informed consent was given from the patients. 
Among couples who underwent IVF or ICSI cycles 
because of tubal, male, ovarian, unexplained, 
endometriosis and both male and female factors, 
60 women at risk of developing OHSS were 
included in this study. The definition of risk was: 
the presence of pre- ovulatory follicles ≥ 20 in both 
ovaries, most of follicles were > 15 mm and at 
least 3 follicles ≥ 18mm were present. The E2 level 
was ≥ 2500 pg/ml.  
 
Stimulation protocol 
      All women were down regulated according to 
the long protocol with Gonadotropin-releasing 
hormone analogue (GnRH-a) subcutaneously 
(Buserelin, Hoechst, Germany). Then, daily 
administration of human menopausal gonadotropin 
(hMG) (Menogon, Ferring, Germany) was added. 
Serum E2 concentrations were measured with 
Enzyme-Linked Immunosorbent Assay (ELISA, 
DRG Instruments GmbH, Germany) at the Yazd 
Research and Clinical Center for Infertility. 
Patients at risk of developing OHSS, who did not 
have a tendency to cancel their cycle, were divided 
into two groups as patient's convenience. Group A 
(coasting group): gonadotropins were withheld 
(while GnRH–a was maintained), until the serum 
level of E2 started to decline. In group B 
(Cabergoline group): hCG was administered and 
the patients received 0.5 mg per day Cabergoline 
orally from the day of hCG for 8 days. Luteal 
phase was supported by administration of 
progesterone in oil 100mg per day for 14 days and 
was continued if pregnancy occurred. Embryo 
culture and Embryo Transfer (ET) procedure were 
carried out in both groups in a similar fashion. 
Patients were monitored every 48 h from the day 
of hCG until the day 8 for the presence of 
symptoms and signs of severe OHSS and 
Hemoglobin (Hb) and Hematocrit (HCT) was 
measured. Clinical pregnancy was defined as the 
presence of gestational sac or cardiac activity 3 
weeks after ET. 
 
Statistical analysis 
     The Statistical Package for the Social Sciences 
15.0 software was used to analyse data of all 
randomized patients. To control for the non-normal 
distribution of the data, Mann-whitney and X2 tests 
were used when appropriate, for the small number 
of cases, Fisher’s exact test was used for the 
comparison of frequencies. A p<0.05 was 
considered statistically significant.     
 
Results 
 
     Between July 2006 and July 2007, we studied 
60 patients at Yazd Research and Clinical Center 
for Infertility which is a famous referral University 
center in Iran. In total, 30 patients in coasting and 
30 patients in Cabergoline group were evaluated. 
The mean age was 28.37±3.2 years in coasting and 
29.63±4.4 years in Cabergoline group (p=0.209). 
The mean duration of infertility was 8.66±3.55 
years in coasting and 8.16±4.8 years in 
Cabergoline group (p=0.650). The mean serum E2 
level on day of hCG was 3035.40±1105 pg/ml in 
coasting and 3012.86 ± 512 pg /ml in Cabergoline 
group (p=0.232). There was no significant 
differences in etiology of infertility between two 
groups (p=0.542). The mean duration of coasting 
in coasting group was 3.20±0.76 days (2-5 days). 
One patient in coasting and one patient in 
Cabergoline group had very bad quality embryos 
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and lead to cycle cancellation before ET. The mean 
number of retrieved oocytes (p=0.001), good 
quality oocytes (p=0.002), metaphase II oocytes 
(p=0.0001) and the mean number of embryos 
obtained was significantly higher in Cabergoline 
group than coasting group (p=0.020). The 
percentage of good quality oocytes (the number of 
good quality oocytes per number of oocytes 
retrieved ×100) was higher in coasting group 
(p=0.061). The percentage of metaphase II oocytes 
(the number of metaphase II oocytes per number of 
oocytes retrieved ×100) was significantly higher in 
coasting group (p=0.001). Fertilization rate was 
also significantly higher in coasting than 
Cabergoline group (p=0.001). One patient in 
coasting group had very bad oocytes and the cycle 
was cancelled. The quality of embryos was similar 
in both group (p=0.600). The clinical pregnancy 
rate per ovum pick–up was higher in Cabergoline 
than coasting group (p=0.285). A total of 4 
pregnancies occurred in coasting group. All 
pregnancies were singleton and there were 2 early 
miscarriages in coasting group (before 8 week of 
gestation). Eight pregnancies occurred in 
Cabergoline group, 2 of these were twin 
pregnancies. Implantation rate was higher in 
Cabergoline than coasting group, but the difference 
was not significant (p=0.060). Four patients in 
coasting group and 5 patients in Cabergoline group 
developed severe OHSS and were hospitalized. 
One patient from each group required 
parasynthesis and for remaining patients infusion 
of normal saline was performed. The incidence of 
severe OHSS was similar in coasting (13.3%) and 
in Cabergoline (16.7%) group (p=0.100). 
 
Table I.  Basic characteristics and early results of patients at risk of OHSS in two groups.
Data are presented as mean(SD); ausing independent samples t-test; busing Mann- Whitney test. 
 
Table II. Clinical outcomes of patients at risk of OHSS in two groups. 
aData are presented as mean(SD); busing independent samples t-test; cdata are presented as n/N (%): n, number of 
patients with the quality, N, total number of the participants in this group; dusing Pearson chi-square test with continuity 
correction.
 
Discussion 
 
     OHSS is the major complication of ovarian 
stimulation and its most severe form can even 
threaten the patient’s life. Several strategies for 
preventing the syndrome have been described. The 
safest strategy is to cancel the cycle. However, it 
should be considered that any form of cancellation 
is associated with emotional and financial costs to 
the couple involved.  It is also possible to avoid 
embryo transfer and freeze all embryos (16). 
Another approach for the prevention of OHSS is 
follicular aspiration prior to hCG administration 
(8). One popular method for reducing the risk of 
syndrome is withholding gonadotropin 
administration and postponing the hCG injection, 
while continuing GnRH agonists. This modality 
has been termed coasting (17). In our previous 
study, no significant difference was observed in 
terms of pregnancy rate and severe OHSS when 
coasting was compared with follicular aspiration 
(18). 
     Recently, Cabergoline has been successfully 
used for high risk patients and has reduced the 
             Coasting (n=30) 
 
            Cabergoline (n=30)                 p-value 
Age (years) 28.37(3.20) 
 
29.63(4.42) 0. 209a 
Duration of infertility (years)                   8.60(3.50) 
 
                     8.1(4.8)              0.650a 
E2 on day of hCG (pg/ml)                 3035(1105.0) 
 
                   3012(512)              0.232b 
Number of retrieved oocytes                   6.47(2.64) 
 
                   12.60(5.26) 0.001b 
Number of good quality oocytes                   4.50(2.51) 
 
                     7.27(3.76) 0.002b 
Number of metaphase II oocytes                   6.17(2.96) 
 
                   10.17(4.06)    0.0001 b 
Number of embryos obtained                   5.07(2.44) 
 
                     7.20(3.60) 0.020b 
Number of embryos transferred                     2.37(0.66) 
 
                     2.30(0.83)  0.774 b 
Score of embryos                 17.23(3.52) 
 
                   16.63(4.42) 0.600b 
Percentage of good quality oocytes                  66.98(23.34) 
 
                   55.82(21.91) 0.061a 
Percentage of metaphase II oocytes                 95.00(20.12) 
 
                   81.96(18.75) 0.001b 
 Coasting (n=30)       Cabergoline (n=30) 
 
             p-value 
Fertilization rate a 79.07(21.95) 
 
59.94±18.03            0.001b 
Implantation rate (%)c                         4/71(5.6) 
 
                         10/69(14.4)            0.060d 
Clinical pregnancy rate (%)c 4/30(13.3) 
 
                           8/30(26.7)            0.285d 
Severe OHSS(%)c 4/30(13.3) 
 
                           5/30(16.7)            0.100d 
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severity of OHSS (19). It has been shown that 
Cabergoline could reverse increased vascular 
permeability in hyperstimulated animals by 
inhibition of VEGFR2 phosphorylation. In animal 
studies, it has been shown that low dose 
Cabergoline blocked some specific VEGFR2 
phosphorylation sites. Therefore, changes in 
VEGFR2 induced by low dose Cabergoline 
reversed the occurrence of increased vascular 
permeability without altering angiogenesis (20). 
The use of Cabergoline for prevention of OHSS 
neither reduced pregnancy nor implantation rate 
(19). 
     Coasting has proven to be an effective method 
to reduce the development of severe OHSS in high 
risk patients. It has been suggested that 
withholding gonadotropins may increase the rate of 
granulosa cell apoptosis (21). This may cause 
atresia of a large number of small follicles, thus 
leading to a reduction in serum E2 concentration 
and vasoactive mediators (22). The decreased 
serum FSH concentrations down regulates the LH 
receptors of the follicles, thus making fewer 
oocytes available for maturation by hCG. At 
ovarian puncture, oocytes which fail to undergo the 
final maturation, stick to the follicle wall and are 
not retrieved. The end result is reduction of 
chemical mediators that cause hyperpermeability 
and a reduction in the number of oocytes retrieved 
(23).  
     In our study like the studies mentioned above, 
the number of retrieved oocytes, good quality and 
mature oocytes, were significantly lower in 
coasting group. But the percentage of mature 
oocytes and the fertilization rate were significantly 
higher in coasting than Cabergoline group. Clinical 
pregnancy and implantation rate were higher in 
Cabergoline group.  
     Since, oocyte quality was not affected by 
coasting; it seems that the receptivity of the 
endometrium was affected. Our results, like those 
of Tortoriello et al (1998) and Ulug et al (2002) 
suggest that coasting for > 3 days may reduces the 
implantation and pregnancy rates (21,24). 
However, Cabergoline has no teratogenic effects 
on fetus (25, 26).  
     In conclusion, coasting is a popular and 
effective method to reduce OHSS rates, but our 
study showed that this procedure appears to be 
associated with a reduced oocyte   retrieval rate, 
and also reduced endometrial receptivity. 
Cabergoline administration was as effective as 
coasting for prevention of early severe OHSS. This 
method is a pathophysiological approach, time-
saving and lead to higher pregnancy rate than 
coasting. However further studies with more cases 
are needed. 
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